header logo image


Page 9«..891011..2030..»

Archive for April, 2020

Animal Stem Cell Therapy Market Is Set To Experience Revolutionary Growth By 2025 – Cole of Duty

Saturday, April 25th, 2020

The Animal Stem Cell Therapy report provides independent information about the Animal Stem Cell Therapy industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies profiles including business overview and recent development.

Animal Stem Cell Therapy MarketLatest Research Report 2020:

Download Premium Sample Copy Of This Report: Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Animal Stem Cell Therapy Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Animal Stem Cell Therapy Market: Products in the Animal Stem Cell Therapy classification furnish clients with assets to get ready for tests, tests, and evaluations.

Animal Stem Cell Therapy Market Report Covers the Following Segments:

Segment1: By Type, Dogs, Horses, Others, By Application, Veterinary Hospitals, Research Organizations

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Animal Stem Cell Therapy Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Animal Stem Cell Therapy Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Animal Stem Cell Therapy Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Animal Stem Cell Therapy Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Animal Stem Cell Therapy Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Animal Stem Cell Therapy Market.

Market Forecast:Here, the report offers a complete forecast of the global Animal Stem Cell Therapy Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://www.marketwatch.com/press-release/at-1905-cagr-pop-up-cinema-market-size-to-surpass-us-197229-million-by-2025-2020-04-24

https://www.marketwatch.com/press-release/at-1905-cagr-pop-up-cinema-market-size-to-surpass-us-197229-million-by-2025-2020-04-24

https://www.marketwatch.com/press-release/ipaas-integration-platform-as-a-service-market-size-share-application-analysis-regional-outlook-growth-trends-top-key-players-and-competitive-strategiesforecast-to-2025-2020-04-24?tesla=y

https://www.marketwatch.com/press-release/microwave-transmission-equipment-market-2020-share-trends-segmentation-and-forecast-by-2025-cagr-of-314-2020-04-24-61763810?tesla=y

http://marketwatch.com/press-release/military-drone-market-share-size-future-demand-global-research-top-leading-player-emerging-trends-region-by-forecast-to-2025-2020-04-24?tesla=y

Read the original here:
Animal Stem Cell Therapy Market Is Set To Experience Revolutionary Growth By 2025 - Cole of Duty

Read More...

Global Cell Sorting Market 2020 Industry Analysis by Manufacturers, Type, Application, End-User and Forecast 2025 – Bandera County Courier

Saturday, April 25th, 2020

A new research study titled Global Cell Sorting Market Report 2020, Forecast to 2025 has been presented by Magnifier Research which offers a comprehensive analysis on the market. Users can benefit from this complete market research report with all the required useful information about this market. The report covers the important components related to the top sellers of the global Cell Sorting industry that influence the market. However, it inspects the primary formats changing the dynamics of the market. Likewise, it covers related current affairs, which will be influencing the market. What more, it simplifies the essential sections and also the sub-sections that represents the recent zone.

Key Components Covered in The Report:

The research document is a detailed study on the growth, investment opportunities, market statistics, growing competition analysis, major key players, industry facts, important figures, sales, prices, revenues, gross margins, market shares, business strategies, top regions, demand, and developments. The report further estimates the global Cell Sorting industry esteem chain, powerful business strategies, cost, structure, creation limit, conveyance, market range, and limits usage rate. The market provides basic information of market members and organizing profiling, contact data, item/benefit beds, income development, revenue generation, and gross deals. This study also provides sales, revenue, and market share for each player covered in this report for a period between 2015 and 2020.

DOWNLOAD FREE SAMPLE REPORT: https://www.magnifierresearch.com/report-detail/37752/request-sample

Following are the topmost key players covered in this global Cell Sorting market research report:- NanoCellect Biomedical, Innovative Biochips, Cesca Therapeutics, Fluidigm, LumaCyte, Union Biometrica, LevitasBio, RareCyte, Cytonome, Namocell, STEMCELL Technologies, Akadeum Life Sciences

Together with geography at the worldwide forecast to 2025 is just absolutely professional and thorough. Moreover, the research study lists the major regional countries, focusing on the remarkable regions:- North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa).

The market segment based on product type includes:- Cancer Cell, Immune Cells, Microbial Cell, Red Blood Cell/Platelet, Stem Cell, Other

Applications mentioned in this report:- Cell Research, Biomedical Diagnosis, Other

Furthermore, the global Cell Sorting market has been divided into types, applications, and regions. This data provides a detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market. The report further includes market shares for 2015 and 2025, for each of the above-mentioned segments. It also highlights the export and import of the market. It also analyses the regional distribution of the industry in terms of development trends.

ACCESS FULL REPORT: https://www.magnifierresearch.com/report/global-cell-sorting-market-report-2020-forecast-to-37752.html

Points Covered In This Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@magnifierresearch.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@magnifierresearch.comWeb: http://www.magnifierresearch.com

See more here:
Global Cell Sorting Market 2020 Industry Analysis by Manufacturers, Type, Application, End-User and Forecast 2025 - Bandera County Courier

Read More...

Stem Cell Therapy Market Overview by 2026: Verified Market Research – Cole of Duty

Saturday, April 25th, 2020

Allosource

Global Stem Cell Therapy Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=COD&utm_medium=002

Global Stem Cell Therapy Market Regions and Countries Level Analysis

The regional analysis is a very complete part of this report. This segmentation highlights Stem Cell Therapy sales at regional and national levels. This data provides a detailed and accurate analysis of volume by country and an analysis of market size by region of the world market.

The report provides an in-depth assessment of growth and other aspects of the market in key countries such as the United States, Canada, Mexico, Germany, France, the United Kingdom, Russia and the United States Italy, China, Japan, South Korea, India, Australia, Brazil and Saudi Arabia. The chapter on the competitive landscape of the global market report contains important information on market participants such as business overview, total sales (financial data), market potential, global presence, Stem Cell Therapy sales and earnings, market share, prices, production locations and facilities, products offered and applied strategies. This study provides Stem Cell Therapy sales, revenue, and market share for each player covered in this report for a period between 2016 and 2020.

Why choose us:

We offer state of the art critical reports with accurate information about the future of the market.

Our reports have been evaluated by some industry experts in the market, which makes them beneficial for the company to maximize their return on investment.

We provide a full graphical representation of information, strategic recommendations and analysis tool results to provide a sophisticated landscape and highlight key market players. This detailed market assessment will help the company increase its efficiency.

The dynamics of supply and demand shown in the report offer a 360-degree view of the market.

Our report helps readers decipher the current and future constraints of the Stem Cell Therapy market and formulate optimal business strategies to maximize market growth.

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Stem Cell Therapy market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Stem Cell Therapy market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Stem Cell Therapy Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=COD&utm_medium=002

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Tags: Stem Cell Therapy Market Size, Stem Cell Therapy Market Trends, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Analysis

Continue reading here:
Stem Cell Therapy Market Overview by 2026: Verified Market Research - Cole of Duty

Read More...

Cover Corona Outbreak: Hematologic Malignancies Market is expected to grow at a CAGR of xx% during the forecast period from 2019-2025 – Cole of Duty

Saturday, April 25th, 2020

Hematologic Malignancies MarketLatest Research Report 2020:

The Hematologic Malignancies report provides an independent information about the Hematologic Malignancies industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies

Download Premium Sample Copy Of This Report:Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Hematologic Malignancies Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Hematologic Malignancies Market: Products in the Hematologic Malignancies classification furnish clients with assets to get ready for tests, tests, and evaluations.

Major Company Profiles Covered in This Report

Pfizer, Inc., F. Hoffmann-LA Roche ltd, Sanofi-Aventis, Bristol-Myers Squibb Company, AbbVie, Inc., Novartis AG, GlaxoSmithKline PLC, Celgene Corporation, Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company limited,

Hematologic Malignancies Market Report Covers the Following Segments:<

Market segment by Type, the product can be split into

Leukemia, Lymphoma, Multiple Myeloma, Others,

Market segment by Application, split into

Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, Others,

Market segment by Regions/Countries, this report covers

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

North America

Europe

Asia-Pacific

South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Hematologic Malignancies Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Hematologic Malignancies Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Hematologic Malignancies Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Hematologic Malignancies Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Hematologic Malignancies Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Hematologic Malignancies Market.

Market Forecast:Here, the report offers a complete forecast of the global Hematologic Malignancies Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Read the original:
Cover Corona Outbreak: Hematologic Malignancies Market is expected to grow at a CAGR of xx% during the forecast period from 2019-2025 - Cole of Duty

Read More...

Global IT Outsourcing Managed Service Market 2020: COVID 19 Breakdown Impact, Industry Analysis, Players, Type, Applications, Size, Share, Growth,…

Saturday, April 25th, 2020

In Global IT Outsourcing Managed Service Market Research Report, the study analysis was given on a worldwide scale, for instance, present and traditional IT Outsourcing Managed Service growth analysis, competitive analysis, and also the growth prospects of the central regions. The report gives an exhaustive investigation of this market provides an analysis of the industry trends in each of the sub-segments, from sales, revenue and consumption. A quantitative and qualitative analysis of the main players in Global and country level is introduced, from the perspective of sales, revenue and price.

Request a sample of IT Outsourcing Managed Service Market report @https://martresearch.com/contact/request-sample/5/32559

Snapshot:The global IT Outsourcing Managed Service market size is estimated at xxx million USD with a CAGR xx% from 2015-2019 and is expected to reach xxx Million USD in 2020 with a CAGR xx% from 2020 to 2025. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of IT Outsourcing Managed Service by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

Product Type Coverage(Market Size & Forecast, Major Company of Product Type etc.):

IT ConsultingEquipment And SoftwareNetwork SystemOthers

Company Coverage(Company Profile, Sales Revenue, Price, Gross Margin, Main Products etc.):

IBMAccentureWiproCognizantDXC TechnologiesHCLHPInfosysCapgeminiNTT DataCGISAP

Application Coverage(Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):

Traditional IndustryHigh TechOthers

Region Coverage(Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)Europe (Germany, U.K., France, Italy, Russia, Spain etc.)Asia-Pacific (China, India, Japan, Southeast Asia etc.)South America (Brazil, Argentina etc.)Middle East & Africa (Saudi Arabia, South Africa etc.)

At the upcoming section, this report discusses industrial policy, economic environment, in addition cost structures of the industry. And this report encompasses the fundamental dynamics of the market which include drivers, opportunities, and challenges faced by the industry. Additionally, this report showed a keen market study of the main consumers, raw material manufacturers and distributors, etc.

Buy The Report @https://martresearch.com/paymentform/5/32559/Single_User

Major Point of TOC:

Table of Content1 Industry Overview2 Industry Environment (PEST Analysis)3 IT Outsourcing Managed Service Market by Type4 Major Companies List5 Market Competition6 Demand by End Market7 Region Operation8 Marketing & Price9 Research Conclusion

About us:Research is and will always be the key to success and growth for any industry. Most organizations invest a major chunk of their resources viz. time, money and manpower in research to achieve new breakthroughs in their businesses. The outcome might not always be as expected thereby arising the need for precise, factual and high-quality data backing your research. This is where MART RESEARCH steps in and caters its expertise in the domain of market research reports to industries across varied sectors.

Contact Us:

Mart Research[emailprotected]+1-857-300-1122

Link:
Global IT Outsourcing Managed Service Market 2020: COVID 19 Breakdown Impact, Industry Analysis, Players, Type, Applications, Size, Share, Growth,...

Read More...

Cell Isolation/Cell Separation Market 2020: Opportunities in Grooming Regions Thermo Fisher Scientific, Merck Millipore, Beckman Coulter and Others -…

Saturday, April 25th, 2020

Futuristic Reports, The growth and development of Global Cell Isolation/Cell Separation Market Report 2020 by Players, Regions, Type, and Application, forecast to 2026 provides industry analysis and forecast from 2020-2026. Global Cell Isolation/Cell Separation Market analysis delivers important insights and provides a competitive and useful advantage to the pursuers. Cell Isolation/Cell Separation processes, economic growth is analyzed as well. The data chart is also backed up by using statistical tools.

Simultaneously, we classify different Cell Isolation/Cell Separation markets based on their definitions. Downstream consumers and upstream materials scrutiny are also carried out. Each segment includes an in-depth explanation of the factors that are useful to drive and restrain it.

Key Players Mentioned in the study are Thermo Fisher Scientific, Merck Millipore, Beckman Coulter, Stemcell Technologies, Pluriselect Life Science, Miltenyi Biotec, GE Healthcare, BD Bioscience, Terumo BCT

For Better Understanding, Download FREE Sample Copy of Cell Isolation/Cell Separation Market Report @ https://www.futuristicreports.com/request-sample/3907

Key Issues Addressed by Cell Isolation/Cell Separation Market: It is very significant to have Cell Isolation/Cell Separation segmentation analysis to figure out the essential factors of growth and development of the market in a particular sector. The Cell Isolation/Cell Separation report offers well summarized and reliable information about every segment of growth, development, production, demand, types, application of the specific product which will be useful for players to focus and highlight on.

Businesses Segmentation of Cell Isolation/Cell Separation Market:

On the basis on the applications, this report focuses on the status and Cell Isolation/Cell Separation outlook for major applications/end users, sales volume, and growth rate for each application, including-

Biotechnology Research Center Hospital Others

On the basis of types/products, this Cell Isolation/Cell Separation report displays the revenue (Million USD), product price, market share, and growth rate of each type, split into-

Instrument Reagent Others

Grab Best Discount on Cell Isolation/Cell Separation Market Research Report [Single User | Multi User | Corporate Users] @ https://www.futuristicreports.com/check-discount/3907

NOTE: Our team is studying Covid-19 impact analysis on various industry verticals and Country Level impact for a better analysis of markets and industries. The 2020 latest edition of this report is entitled to provide additional commentary on latest scenario, economic slowdown and COVID-19 impact on overall industry. Further it will also provide qualitative information about when industry could come back on track and what possible measures industry players are taking to deal with current situation.

OR

You just drop an Email to:[emailprotected] us if you are looking for any Economical shift towards the New Normal on any Country or Industry Verticals.

Cell Isolation/Cell Separation Market Regional Analysis Includes:

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) North America (the United States, Mexico, and Canada.) South America (Brazil etc.) The Middle East and Africa (GCC Countries and Egypt.)

Cell Isolation/Cell Separation Insights that Study is going to provide:

Gain perceptive study of this current Cell Isolation/Cell Separation sector and also possess a comprehension of the industry; Describe the Cell Isolation/Cell Separation advancements, key issues, and methods to moderate the advancement threats; Competitors In this chapter, leading players are studied with respect to their company profile, product portfolio, capacity, price, cost, and revenue. A separate chapter on Cell Isolation/Cell Separation market structure to gain insights on Leaders confrontational towards market [Merger and Acquisition / Recent Investment and Key Developments] Patent Analysis** Number of patents filed in recent years.

Table of Content:

Global Cell Isolation/Cell Separation Market Size, Status and Forecast 20261. Market Introduction and Market Overview2. Industry Chain Analysis3. Cell Isolation/Cell Separation Market, by Type4. Cell Isolation/Cell Separation Market, by Application5. Production, Value ($) by Regions6. Production, Consumption, Export, Import by Regions (2016-2020)7. Market Status and SWOT Analysis by Regions (Sales Point)8. Competitive Landscape9. Analysis and Forecast by Type and Application10. Channel Analysis11. New Project Feasibility Analysis12. Market Forecast 2020-202613. Conclusion

Enquire More Before Buying @ https://www.futuristicreports.com/send-an-enquiry/3907

For More Information Kindly Contact:

Futuristic ReportsTel: +1-408-520-9037Media Release:https://www.futuristicreports.com/press-releases

Follow us on Blogger @https://futuristicreports.blogspot.com/

See more here:
Cell Isolation/Cell Separation Market 2020: Opportunities in Grooming Regions Thermo Fisher Scientific, Merck Millipore, Beckman Coulter and Others -...

Read More...

Bayer, Novartis, and Trump convicted by Nature – European Biotechnology

Friday, April 24th, 2020

The politically overhyped use of old malaria drugs in combination with COVID-19-specific candidates has been demonstrated to be dangerous, reports Nature Medicine.

In the prestigous paper Nature Medicine, cardiologists under Lior Jankelson report that patients with COVID-19 who were on a regimen of Novartis AGs generic malaria drug hydroxychloroquine and the antibiotic azithromycin experienced electrocardiogram abnormalities. Previous reports demonstrated that the same is true for chloroquine phosphate, an old malaria drug originally developed at Bayer AG. The authorsassessed 84 patients with COVID-19 treated at a centre in New York, USA.

Azithromycin in combination with antimalarial hydroxychloroquine has been touted by President Donald Trump as a possible "game changer" in COVID-19. Former BARDA head Rick Bright was fired because he resisted political interventions to push the use of chloroquine derivatives to treat COVID-19 despite scientific evidence of efficacy and safety according to current authorisation standards. Biocentury reported previously that Trumps preference for the cheap but antiquated malaria treatments looked more like political science than actually based on scientific evidence. Several clinical programmes coordinated by the WHO , the European Union, and the UK promote clinical testing of combinations with either chloroquine phosphate or hydroxychloroquine and may cause thousands of deaths unless they were not updated to include new findings.

Several reports demonstrated that both medications increase the risk of various types of cardiac rhythm abnormalities, such as QTc-interval prolongation and drug-inducedtorsades de pointes, and sudden cardiac death. The QTc interval is measured by an electrocardiogram and represents the time it takes for a heart to recharge between beats. A prolonged QTc interval puts a patient at risk for arrhythmia and sudden cardiac death.

Now, Jankelson and colleagues reviewed the charts and followed the QTc interval of 84 patients with COVID-19 on a 5-day oral regiment of hydroxychloroquine and azithromycin. The patients were, on average, 63 years of age and74% were male. After the patients were administered the drugs, the authors followed up with an electrocardiogram. They observed a prolonged QTc in most patients. The QTc was severely prolonged in 11% of the patients, which put them at high risk of arrhythmia and sudden cardiac death. Four patients in the cohort died from multiple organ failure a characteristic of septic shock without evidence of arrhythmia and without severe QTc prolongation.

Jankelson and colleagues found that most patients with COVID-19 who were treated with hydroxychloroquine and azithromycin experienced QTc prolongation. This may have been exacerbated by other pre-existing conditions and the severity of the SARS-CoV-2 infection. The authors conclude that the QTc in patients with COVID-19 who are treated with hydroxychloroquine and azithromycin should be monitored constantly, especially for patients with additional illnesses and those who are being treated with other QT-prolonging medications.

Continue reading here:
Bayer, Novartis, and Trump convicted by Nature - European Biotechnology

Read More...

Trends of Biotechnology Separation Systems Market Reviewed for 2020 with Industr – News.MarketSizeForecasters.com

Friday, April 24th, 2020

The ' Biotechnology Separation Systems market' research report is latest addition by Market Study Report, LLC, that elucidates relevant market and competitive insights as well as regional and consumer information. In a nutshell, the research study covers every pivotal aspect of this business sphere that influences the existing trends, profitability position, market share, market size, regional valuation, and business expansion plans of key players in the Biotechnology Separation Systems market.

The latest report on the Biotechnology Separation Systems market is a depiction of the end-to-end analysis of this business vertical, and includes quite some information about the industry, with respect to pivotal parameters such as the most recent market tendencies, present revenue, market share, market size, periodic deliverables, and profits estimations for the forecast period.

Request a sample Report of Biotechnology Separation Systems Market at:https://www.marketstudyreport.com/request-a-sample/2484141?utm_source=marketsizeforecaster.com&utm_medium=TS

A brief overview of how the Biotechnology Separation Systems market will perform over the projected timeframe has been given in the report. Also, details about the driving aspects influencing the market dynamics as well as the growth rate that the industry is expected to register over the forecast duration have been delivered. Additionally, the Biotechnology Separation Systems market report also delivers a brief of the challenges that this vertical is defined by, in conjunction with the growth opportunities that this business space is remnant of.

Main pointers highlighted in the Biotechnology Separation Systems market report:

Unveiling the Biotechnology Separation Systems market with regards to the regional terrain:

Biotechnology Separation Systems Market Segmentation: USA, Europe, Japan, China, India, South East Asia.

A gist of the details presented in the market report with regards to the major industry indicators:

Ask for Discount on Biotechnology Separation Systems Market Report at:https://www.marketstudyreport.com/check-for-discount/2484141?utm_source=marketsizeforecaster.com&utm_medium=TS

A comprehensive gist of the Biotechnology Separation Systems market with regards to the product and application spectrums:

Product landscape:

Product types: Membrane Filtration, Liquid Chromatography, Centrifuge, Electrophoresis, Flow Cytometry and Others

Key insights presented in the report:

Application landscape:

Application segmentation: Commercial and Scientific Research

Specifics provided in the report:

Other major pointers included in the report:

Some details about the competitive terrain of the Biotechnology Separation Systems market include:

Vendor base of the industry: Danaher, Sartorius Stedim Biotech, Thermo Fisher Scientific, Merck, GE Healthcare, BD, Alfa Wassermann, Agilent, Shimadzu, Sysmex, Bio-Rad Laboratories, PerkinElmer, Alfa Laval, Illumina, 3M Purification, Novasep, Hitachi Koki, Affymetrix, Waters and Repligen

Competitive analysis parameters enlisted in the report include:

The Biotechnology Separation Systems market evaluation exhibits substantial details about the aspects like market concentration ratio.

For More Details On this Report: https://www.marketstudyreport.com/reports/global-biotechnology-separation-systems-market-growth-2020-2025

Some of the Major Highlights of TOC covers:

Development Trend of Analysis of Biotechnology Separation Systems Market

Marketing Channel

Market Dynamics

Methodology/Research Approach

Related Reports:

2. Global Low-Earth Orbit Satellite Market Growth 2020-2025Low-Earth Orbit Satellite Market report characterize imperative Portion and contenders of the market regarding market estimate, volume, esteem. This report likewise covers every one of the locales and nations of the world, which demonstrates a territorial improvement status, it additionally incorporates Business Profile, Introduction, Revenue and so on.Read More: https://www.marketstudyreport.com/reports/global-low-earth-orbit-satellite-market-growth-2020-2025

Read More Reports On: https://www.marketwatch.com/press-release/military-laser-systems-market-analysis-with-key-players-applications-trends-and-forecast-to-2025-2020-04-24

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email:

Continued here:
Trends of Biotechnology Separation Systems Market Reviewed for 2020 with Industr - News.MarketSizeForecasters.com

Read More...

Is SAGE Therapeutics Inc (SAGE) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

Friday, April 24th, 2020

A rating of 18 puts SAGE Therapeutics Inc (SAGE) near the bottom of the Biotechnology industry according to InvestorsObserver. SAGE Therapeutics Inc's score of 18 means it scores higher than 18% of stocks in the industry. SAGE Therapeutics Inc also received an overall rating of 35, putting it above 35% of all stocks. Biotechnology is ranked 10 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

SAGE Therapeutics Inc (SAGE) stock is trading at $38.00 as of 1:22 PM on Friday, Apr 24, a rise of $1.76, or 4.86% from the previous closing price of $36.24. The stock has traded between $35.62 and $38.03 so far today. Volume today is light. So far 545,172 shares have traded compared to average volume of 1,562,765 shares.

To see InvestorsObserver's Sentiment Score for SAGE Therapeutics Inc click here.

Go here to see the original:
Is SAGE Therapeutics Inc (SAGE) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Read More...

Will These Thrive Or Dive ? Vir Biotechnology (VIR), Pinnacle Financial Partners (PNFP) – US Post News

Friday, April 24th, 2020

The recent performance of Vir Biotechnology (NASDAQ:VIR) stock in the market spoke loud and clear to investors as VIR saw more than 1.13M shares in trading volumes in the last trading session, way higher than the average trading volume of 1.13M shares by far recorded in the movement of Vir Biotechnology (VIR). At the time the stock opened at the value of $29.55, making it a high for the given period, the value of the stock jumped by 3.56%. After the increase, VIR touched a low price of $29.55, calling it a day with a closing price of $30.08, which means that the price of VIR went 1.6 below the opening price on the mentioned day.

Given the most recent momentum in the market in the price movement of VIR stock, some strong opinions on the matter of investing in the companys stock started to take shape, which is how analysts are predicting an estimated price of $34.33 for VIR within consensus. The estimated price would demand a set of gains in total of -37.91%, which goes higher than the most recent closing price, indicating that the stock is in for bullish trends. Other indicators are hinting that the stock could reach an outstanding figure in the market share, which is currently set at 100.45M in the public float and 3.41B US dollars in market capitalization.

When it comes to the technical analysis of VIR stock, there are more than several important indicators on the companys success in the market, one of those being the Relative Strength Indicator (RSI), which can show, just as Stochastic measures, what is going on with the value of the stock beneath the data. This value may also indicate that the stock will go sideways rather than up or down, also indicating that the price could stay where it is for quite some time. When it comes to Stochastic reading, VIR stock are showing 26.08% in results, indicating that the stock is neither overbought or oversold at the moment, providing it with a neutral within Stochastic reading as well. Additionally, VIR with the present state of 200 MA appear to be indicating bullish trends within the movement of the stock in the market. While other metrics within the technical analysis are due to provide an outline into the value of VIR, the general sentiment in the market is inclined toward positive trends.

With the previous 100-day trading volume average of 543315 shares, Pinnacle Financial Partners (PNFP) recorded a trading volume of 717220 shares, as the stock started the trading session at the value of $34.35, in the end touching the price of $34.88 after jumping by 1.54%.

PNFP stock seem to be going ahead the lowest price in the last 52 weeks with the latest change of 25.47%.Then price of PNFP also went backward in oppose to its average movements recorded in the previous 20 days. The price volatility of PNFP stock during the period of the last months recorded 6.96%, whilst it changed for the week, now showing 5.92% of volatility in the last seven days. The trading distance for this period is set at -7.95% and is presently away from its moving average by -22.96% in the last 50 days. During the period of the last 5 days, PNFP stock lost around -2.84% of its value, now recording a dip by -37.07% reaching an average $55.32 in the period of the last 200 days.During the period of the last 12 months, Pinnacle Financial Partners (PNFP) dropped by -45.50%.

According to the Barcharts scale, the companys consensus rating was unchanged to 4.00 from 4.00, showing an overall improvement during the course of a single month. Based on the latest results, analysts are suggesting that the target price for PNFP stock should be $34.88 per share in the course of the next 12 months. To achieve the target price as suggested by analysts, PNFP should have a spike by 0% in oppose to its present value in the market. Additionally, the current price showcases a discount of 34.19% when compared to the high consensus price target predicted by analysts.

PNFP shares recorded a trading volume of 588569 shares, compared to the volume of 638.57K shares before the last close, presented as its trading average. With the approaching 5.92% during the last seven days, the volatility of PNFP stock remained at 6.96%. During the last trading session, the lost value that PNFP stock recorded was set at the price of $34.88, while the lowest value in the last 52 weeks was set at $27.80. The recovery of the stock in the market has notably added 25.47% of gains since its low value, also recording -0.11% in the period of the last 1 month.

See original here:
Will These Thrive Or Dive ? Vir Biotechnology (VIR), Pinnacle Financial Partners (PNFP) - US Post News

Read More...

Where Does Mesoblast limited (MESO) Stock Fall in the Biotechnology Field? – InvestorsObserver

Friday, April 24th, 2020

Mesoblast limited (MESO) is near the top in its industry group according to InvestorsObserver. MESO gets an overall rating of 82. That means it scores higher than 82 percent of stocks. Mesoblast limited gets a 95 rank in the Biotechnology industry. Biotechnology is number 10 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Mesoblast limited (MESO) stock is trading at $16.61 as of 10:30 AM on Friday, Apr 24, an increase of $10.16, or 157.52% from the previous closing price of $6.45. The stock has traded between $14.33 and $20.57 so far today. Volume today is above average. So far 12,327,011 shares have traded compared to average volume of 428,508 shares.

To screen for more stocks like MESO click here.

Go here to read the rest:
Where Does Mesoblast limited (MESO) Stock Fall in the Biotechnology Field? - InvestorsObserver

Read More...

Why Investors Need To Watch Vir Biotechnology, Inc. (VIR)? – The News Heater

Friday, April 24th, 2020

Vir Biotechnology, Inc. (NASDAQ:VIR) went up by 3.56% from its latest closing price when compared to the 1-year high value of $75.00 and move down -140.77%, while VIR stocks collected +6.21% of gains with the last five trading sessions. Press Release reported on 04/15/20 that VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial

VIR stocks went up by 6.21% for the week, with the monthly drop of -4.89% and a quarterly performance of 83.45%. The simple moving average for the period of the last 20 days is 0.29% for VIR stocks with the simple moving average of 44.30% for the last 200 days.

Many brokerage firms have already submitted their reports for VIR stocks, with JP Morgan repeating the rating for VIR shares by setting it to Underweight. The predicted price for VIR socks in the upcoming period according to JP Morgan is $26 based on the research report published on March 19, 2020.

Goldman, on the other hand, stated in their research note that they expect to see VIR stock at the price of $26. The rating they have provided for VIR stocks is Neutral according to the report published on March 13, 2020.

Robert W. Baird gave Underperform rating to VIR stocks, setting the target price at $17 in the report published on February 27, 2020.

After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, Vir Biotechnology, Inc. was unable to take a rebound, for now settling with -58.47% of loss for the given period.

The stock volatility was left at 11.09%, however, within the period of a single month, the volatility rate increased by 7.37%, while the shares surge at the distance of +1.30% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +70.78% upper at the present time.

In the course of the last 5 trading sessions, VIR went up by +6.21%. In addition, Vir Biotechnology, Inc. saw 147.71% in overturn over the period of a single year with a tendency to cut further gains.

The current profitability levels are settled at -2110.98 for the present operating margin. The net margin for Vir Biotechnology, Inc. stands at -2158.98. Total capital return value is set at -61.54, while invested capital returns managed to touch -62.97.

Based on Vir Biotechnology, Inc. (VIR), the companys capital structure generated 0.27 points for debt to equity in total, while total debt to capital is set at the value of 0.27.

Visit link:
Why Investors Need To Watch Vir Biotechnology, Inc. (VIR)? - The News Heater

Read More...

Insights on the Worldwide Biotechnology Reagents Industry to 2024 – Drivers, Challenges and Trends – ResearchAndMarkets.com – Business Wire

Friday, April 24th, 2020

DUBLIN--(BUSINESS WIRE)--The "Global Biotechnology Reagents Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

The biotechnology reagents market is poised to grow by $ 37.87 bn during 2020-2024 progressing at a CAGR of 8% during the forecast period. The report on the biotechnology reagents market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the presence of high-throughput and novel technologies and high usage of biotechnology reagents in diagnostic and therapeutic applications. In addition, the presence of high-throughput and novel technologies is anticipated to boost the growth of the market as well.

This study identifies the increasing R&D investments by federal agencies and biotechnology firms as one of the prime reasons driving the biotechnology reagents market growth during the next few years.

Companies Mentioned

Key Topics Covered:

1. Executive Summary

2. Market Landscape

3. Market Sizing

4. Five Forces Analysis

5. Market Segmentation by Technology

6. Customer landscape

7. Geographic Landscape

8. Drivers, Challenges, and Trends

9. Vendor Landscape

10. Vendor Analysis

11. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/jdmnpl.

See original here:
Insights on the Worldwide Biotechnology Reagents Industry to 2024 - Drivers, Challenges and Trends - ResearchAndMarkets.com - Business Wire

Read More...

Biotech and Pharmaceutical Stocks Beat the Market in Recessions – Barron’s

Friday, April 24th, 2020

Text size

Looking for a safe harbor during the Covid-19 pandemic? The biotech and pharmaceutical industries deserve a close look, according to SVB Leerink analyst Geoffrey Porges.

The indexes that track the biotech and pharmaceutical sectors outperformed the market in the 2001, 2008-09, and current recessions, he wrote in a Friday morning note.

On average, the biotechnology Indexes declined -1% during the three economic downturns, compared with the pharmaceutical indexs -10% and the S&P 500 indexs -20%. On a relative basis, biotech and pharmaceutical Indices outperformed the S&P 500 by 18% and 10%, respectively, Porges noted.

One likely explanation: People need their medicine, even in a recession. Porges cited published papers showing that pharmaceutical sales volume stayed steady in the U.S. during the 2008-09 recession.

So far this year, biotech indexes and exchange-traded funds have vastly outperformed the market. While the S&P 500 is down 13.4% since the start of the year, the iShares Nasdaq Biotechnology ETF (ticker: IBB) is up 2.2%. The SPDR S&P Biotechnology ETF (XBI) is down 1.4%, while the Nasdaq Biotechnology Index (NBI) is up 2.3%.

Pharmaceutical indexes have also performed well. The NYSE Arca Pharmaceutical index is down 1.1%, while the S&P 500 Pharmaceuticals index is down 0.5%.

Those performances have been boosted by strong showings from large-cap biotech companies like Gilead Sciences (GILD), which is up 19.7% so far this year on excitement over its experimental Covid-19 therapy remdesivir, and Moderna (MRNA), which is up a startling 142.5% so far this year over its Covid-19 vaccine, which is in clinical trials.

Major pharmaceutical companies have also outperformed. Johnson & Johnson (JNJ) is up 6.6%, while Eli Lilly (LLY) is up 21.7%. The company clocked a new 52-week high on Friday morning.

Porges note suggests that all this tracks with the recent history of recessions.

Our analysis of historical recessions suggested that the biotech and pharma indices (and stocks) significantly outperformed the broad market (S&P 500), despite the greater P/E multiple compressions in the healthcare indices, he wrote.

The iShares Nasdaq Biotechnology ETF was up 0.6% in recent trading, while the S&P 500 was up 0.4%.

Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com

Continued here:
Biotech and Pharmaceutical Stocks Beat the Market in Recessions - Barron's

Read More...

Vir Biotechnology, Inc. (VIR) is on the roll with an average volume of 1.13M in the recent 3 months – The InvestChronicle

Friday, April 24th, 2020

Lets start up with the current stock price of Vir Biotechnology, Inc. (VIR), which is $31.15 to be very precise. The Stock rose vividly during the last session to $31.4 after opening rate of $29.55 while the lowest price it went was recorded $29.55 before closing at $30.08.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -58.47% during the 52-week period from high price, and 167.37% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.56 million for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 147.71%, having the revenues showcasing 83.45% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 3.41B, as it employees total of 229 workers.

During the last month, 3 analysts gave the Vir Biotechnology, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 24.32, with a change in the price was noted +19.25. In a similar fashion, Vir Biotechnology, Inc. posted a movement of +161.76% for the period of last 100 days, recording 780,574 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for VIR is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 25.56%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 31.58%. In the last 20 days, the companys Stochastic %K was 27.22% and its Stochastic %D was recorded 25.85%.

Bearing in mind the latest performance of Vir Biotechnology, Inc., several moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 147.71%. The shares increased approximately by 1.57% in the 7-day charts and went up by 6.21% in the period of the last 30 days. Common stock shares were driven by 83.45% during last recorded quarter.

More:
Vir Biotechnology, Inc. (VIR) is on the roll with an average volume of 1.13M in the recent 3 months - The InvestChronicle

Read More...

Impact of COVID-19 Outbreak on Global Briefing 2019 Pharmaceutical and Biotechnology Machines Industry Analyzer Technique, Advancements, Market Size,…

Friday, April 24th, 2020

The report on the Pharmaceutical and Biotechnology Machines market provides a birds eye view of the current proceeding within the Pharmaceutical and Biotechnology Machines market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Pharmaceutical and Biotechnology Machines market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Pharmaceutical and Biotechnology Machines market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The Pharmaceutical and Biotechnology Machines market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Pharmaceutical and Biotechnology Machines market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2553414&source=atm

The major players profiled in this Pharmaceutical and Biotechnology Machines market report include:

The following manufacturers are covered:Air LiquideLinde HealthcarePraxairAir ProductsTaiyo Nippon SansoMatheson GasAtlas Copco ABMesser GroupSOL GroupNorcoSicgil India LimitedShenzhen GaofaShenwei MedicalBeijing OrientNanning Lantian

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeOxygenNitrous OxideMedical AirOthers(Nitrogen, Carbon Dioxide and Helium)

Segment by ApplicationHospitals (Labs & Clinics)Home HealthcareUniversities/Research InstitutionsPharmaceutical & Biotechnology Industries

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2553414&licType=S&source=atm

Key Market Related Questions Addressed in the Report:

Important Information that can be extracted from the Report:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2553414&source=atm

Excerpt from:
Impact of COVID-19 Outbreak on Global Briefing 2019 Pharmaceutical and Biotechnology Machines Industry Analyzer Technique, Advancements, Market Size,...

Read More...

Costa Rica prepares to develop its own coronavirus tests; will announce next steps in facing crisis – The Tico Times

Friday, April 24th, 2020

Costa Rica plans to develop its own test for the coronavirus, President Carlos Alvarado announced Thursday afternoon.

The Costa Rican government is also preparing to announce a roadmap for easing restrictions against the spread of COVID-19.

In addition to the latest coronavirus data, heres what you should know from todays press conference:

The National Center of Biotechnology Innovations is developing a test for the coronavirus that could reduce the countrys burden on international kits, President Alvarado said.

Today, we are announcing that Costa Rica is developing its own tests for COVID-19, here in our country, he said. Facing the situation of high international demand for tests, we have the capability to create them here.

Randall Loaiza, director of the biotechnology laboratory, gave a brief demonstration of the test.

Genetic material will first be extracted from a mucous sample, separating RNA from the rest of the sample.After a purification process, the RNA will be placed into a PCR machine and allowed to reproduce, at which point the presence (or lack thereof) of SARS-CoV-2 can be detected.

By producing its own reagents or by acquiring reagents that are in lower demand, Costa Rica could minimize its dependency on solutions that are in short supply worldwide. (This is similar to a strategycreated by virologists in England.)

Its not just that we want to have a home-brew solution, Loaiza said. Its a need to have a home-brew solution that meets the same standards as the kits.

Theteam working on the new test is comprised of Costa Rican biologists, physicists, virologists, geneticists and biotechnologists.The National Center of Biotechnology Innovations hopes to have its tests approved and distributed in six weeks.

This demonstrates the quality of our human talent and our science, and the solidarity of our country, President Alvarado said.

Costa Rican authorities will announce on Monday plans for the country to ease restrictions that have been established to slow the spread of COVID-19.

The roadmap is designed to allow Costa Rica to gradually relax measures while minimizing the countrys risk for a surge in cases.

The situation of the pandemic is, thanks to all of our efforts, under control, President Alvarado said. But it is a very fragile control.

President Alvarado urged Costa Ricans not to let down their guards and warned that normal wont be the same as it was before.

In response to the coronavirus, Costa Rica has suspended mass gatherings, closed its borders to non-residents and established vehicular restrictions, among other measures.Costa Rica has announced seven-straight decreases in known active coronavirus cases.

Costa Rica coronavirus cases. Click for full size. Tico Times graph.

On May 4, President Alvarado will deliver his annual address to the Legislative Assembly Costa Ricas version of a State of the Union.

Alvarado said Thursday that his speech will focus on how Costa Rica can reactivate its economy and respond with unity to the coronavirus crisis.

Were on one team: Team Costa Rica, he said.If were not careful, we can become a country divided. We have to avoid that at all costs.

Read more here:
Costa Rica prepares to develop its own coronavirus tests; will announce next steps in facing crisis - The Tico Times

Read More...

Boosting the Immune System Really Does Help With COVID-19, Experts Say – Phoenix New Times

Friday, April 24th, 2020

According to some of the more dramatic pandemic predictions, as many as 150 million Americans will come down with COVID-19 before a vaccine becomes widely available. While avoiding it altogether is the ideal scenario, as the virus continues to spread, for many, infection is inevitable.

Given that unfortunate reality, building up a personal defense system against an invisible enemy is paramount, according to the experts.

In March, Banner Health published a blog post: How You Can Boost Your Immune System, with the message: A strong immune system is the ultimate defense against illness, whether its COVID-19, seasonal flu, or something else. The posts advice is largely mundane: Get eight hours of sleep, eat nutritious foods, exercise, hydrate, and do what you can to reduce stress in an incredibly stressful time.

Most people understand that adopting healthier habits is a good idea, but can these habits really boost your immune system so that a coronavirus infection looks more like, say, a common cold? Jessica Lancaster, an immunologist researcher at the Mayo Clinic, thinks its a distinct possibility.

If you had two people with the same virus exposure and very similar genetic makeup, Lancaster said, and if one had been better overall sleeping, eating well, and exercising that person would most likely be much better off than the person who is not caring for themselves as well.

The microscopic novel coronavirus typically enters the body through the nose, she said. From there, it begins a deliberate and dangerous process of multiplying and penetrating deeper down the respiratory tract and into the bloodstream. A spry immune system bolstered by exercise, healthy food, and plenty of sleep will harass the virus before it wreaks the kind of havoc that requires hospitalization, ICU admission, or a ventilator.

Essentially, the immune system is a collection of cells, surveilling our body for unwelcome visitors: viruses, bacteria, various toxins, and cancer. When something isnt right, alarm bells go off and the immune system springs into action to make things right.

Jessica Lancaster, immunologist at the Mayo Clinic

YouTube/Mayo Clinic

Our immune systems ability to react to alarm bells and fight off foreign intruders depends on a multitude of factors. Among them are our age, where we live, what we do for work, and three biggies: good sleep, low stress, and healthy eating. These things have a profound effect on two major contributors to our immune systems sharpness: chronic inflammation and cortisol levels.

In the case of COVID-19, the virus hijacks lung cells and eventually damages them to where they become inflamed. But when there is chronic inflammation in people, such as those with preexisting conditions like heart disease or lung disease, the immune cells are worn out or lulled to sleep.

In these cases, Lancaster said, [immune cells] are kind of used to hearing these signals over and over again. When they have to actually respond to something, they're already exhausted.

For example, if you are regularly exposed to toxic chemicals that cause inflammation, like cigarette smoke, you can have a boy that cried wolf situation, where the body gets jaded to these constant warning signs of trouble and is slower to respond.

For someone with COVID-19, any kind of delayed immune response can be catastrophic.

When you have something that is quite aggressive like coronavirus, which can strike really quickly if you have a lagging immune response, that can be devastating because by the time everything is mobilized, its too late. There's too much damage to the lungs, Lancaster said.

One simple way to avoid inflammation is to avoid overeating. If you eat too many calories, it can be hard for your body to regulate its blood sugar. And that leads to inflammation, Lancaster said, adding that this kind of blood sugar-induced inflammation tends to affect the kidneys, liver, and pancreas.

When it comes to supplements, Lancaster is ambivalent. But she admitted that when she gets sick herself, she takes zinc lozenges. She cited some inconclusive evidence that Vitamin C may have some antiviral properties or may be simply reducing inflammation across the body.

Cortisol is another of the bodys loud alarm bells. It is our primary stress hormone, and according to Lancaster, it can cause drastic changes to the way that your cells can function on a genetic level. A burst of cortisol here or there can help you spring into action to avoid a threat, but too much, too often can leave your body stuck in an uncomfortable, unhealthy kind of overdrive.

Lab research shows that immune cells can't fight viruses as well when they are injected with cortisol. In 2018, researchers at the University of Kent found cortisol levels to be a critical factor at play in leukemia cases, showing that the stress hormone hinders the immune systems ability to incapacitate intruders before they really get destructive.

Reading, meditating, and especially exercising may lower cortisol levels in people.

Exercising has the added benefit of helping you get your eight hours of sleep, all of which helps reduce inflammation and regulate stress hormones.Last week, a cardiovascular researcher at the University of Virginia released findings suggesting that an antioxidant that is naturally released during exercise can significantly reduce the risk of suffering fromacute respiratory distress syndrome, a severe problem that occurs in 20 to 42 percent of hospitalized COVID-19 patients. Exercise, the research found, boosts production of an antioxidant known as extracellular superoxide dismutase, or EcSOD, which "hunts" atomic free radicals that can harm the body's cells.

Beth Jacobs

University of Arizona

"We cannot live in isolation forever, said Zhen Yan of the University of Virginia School of Medicine in an April 15 University of Virginia news release. "Regular exercise has far more health benefits than we know. The protection against this severe respiratory disease condition is just one of the many examples.

Beth Jacobs, a nutritional epidemiologist at the University of Arizona, is wary about making any promises about how any type of immune boosting can influence ones chances of coming down with a bad case of the virus.

"We know essentially nothing about COVID19 yet," she said in a recent interview.

In lieu of more specific knowledge about the virus, she echoes Lancasters sentiments about the importance of healthy habits. When it comes to immunity, she said, it is all about the three interlocked concepts, which are diet, physical activity, and sleep.

Essentially, [sleep] is the time when you're repairing what's happened during the day, Jacobs said. It allows you to heal up to take on the next day.

While science has yet to uncover the inner workings of sleep, Jacob says we can infer its value from its incredible cost. Our ancient ancestors risked being eaten while they laid motionless for hours a day for it, she pointed out.

She urges persistence and patience in developing new, healthy habits, stressing that we are still at the very beginning of the pandemic. Try new recipes and get outside, Jacobs urged.

Use the time to go outside and walk," she said. "And if you've never walked before, just take a 10-minute walk, and then a 15-minute walk next week. Just keep going."

See the article here:
Boosting the Immune System Really Does Help With COVID-19, Experts Say - Phoenix New Times

Read More...

COVID-19 kills more men than women. The immune system may be why – Science News

Friday, April 24th, 2020

With more men than women developingsevere illness and dying from COVID-19, sex differences that influence theimmune system may offer answers.

The bias in COVID-19 deaths appearedin the first reports out of China and has also been revealed in countries thatbreak down their mortality data by sex. Of Italys 21,551 deaths recorded as ofApril 20, 64 percent were men. In Spain, 59 percent of the 12,634 deaths as of April 21 occurred in men. Germany had recorded 4,598deaths by April 21, with 58 percent in men.

The United States does notseparate out national COVID-19 mortality by sex, but some states do. New York hasthe highest number COVID-19 deaths in the country, and as of April 21, 60 percent of 15,302 deaths were in men.

Some of that discrepancycould be because men are more likely than women to have other health problems,such as hypertension and diabetes. These are among the underlying conditionsthat raise the risk for severe COVID-19 disease, the U.S. Centers for Disease Control and Preventionreported April 3.

Another possible culprit isthe immune system itself. The many proteins that work together to defend thebody against viruses do not operate exactly the same way in males and females. Thosebiological differences, driven by sex hormones and genes, may be guarding somewomen from the deadliest complications of COVID-19.

Scientists and journalists share a core belief in questioning, observing and verifying to reach the truth. Science News reports on crucial research and discovery across science disciplines. We need your financial support to make it happen every contribution makes a difference.

In general, females mount astronger immune response than males, studies have found. This makes womenoverall less susceptible to viral infections than men, although how each individualfares is another matter. A stronger immune response also means females are morelikely to develop autoimmune diseases, when the immune system attacks ones owntissue; conversely, a toned down immune response makes males more prone tohaving a host of malignant cancers.

The sources of the stronger femaleimmune response can be found in both the innate and adaptive immune systems,says Sabra Klein, a virologist at the Johns Hopkins University Bloomberg Schoolof Public Health. The innate system provides the first response against a virus,while the adaptive systems contribution is slightly delayed by the time neededto ramp up antibody production against a new intruder.

One component of the innateimmune system is called toll-like receptor 7. This protein can recognizemolecules found on viruses, thereby outing the pathogens as foreign. The genefor toll-like receptor 7 resides on the X chromosome. Because females have twocopies of the X, the body silences one (SN: 4/8/03),allowing for the right dose of X chromosome genes. But some genes escape the shutdown, and there is evidence that this is true for the gene for toll-likereceptor 7, researchers reported in Science Immunology in 2018. That canlead to more of the protein being made, giving females more guards looking outfor intruders.

Having more toll-likereceptor 7 can help jump start and enhance the next steps of the innate immune system.You want fast recognition, you want fast responses, Klein says. This is howyou start to activate the army of immune responses that are going to be neededto clear an infection. One of those steps is the release of interferons,proteins that direct major factions of the bodys immune response. In studiesthat measure levels of interferons in blood or in cells grown in a dish, researchersoverall see greater production of these interferons in females as comparedwith males, says Klein.

As the adaptive immunesystem gears up, women can get a boost over men again. The amount of antibodyproduced, as well as the quality of those antibodies, or the strength withwhich they bind to the virus, tends to be greater in females compared withmales, Klein says. Female mice produced more neutralizing antibodies the type which stop an infection by preventing thevirus from entering cells and more total antibodies against influenza A virus after infection comparedwith males, Klein and colleagues reported in Vaccine in 2011.

The female hormone estrogenalso influences the innate and adaptive immune systems. The hormone can regulatea variety of different genes for immune system proteins. For example, estrogen canstimulate the production of interferons, says Klein. And some of the genes thatare associated with directing the response of B cells, which make antibodies,are regulated by estrogen.

All of these findings comefrom research with other viruses, and havent yet been studied in the contextof COVID-19, Klein says, but they provide us with some clues. At this point,some of the best clues as to why there are discrepancies in how men and womenfare with COVID-19 may come from a study of the disease SARS in mice. The virus that causes SARS shares similarities with the culprit behind COVID-19,SARS-CoV-2 (SN: 2/3/20). And there isevidence that during the SARS epidemic of 2002-2003, which had close to 800deaths, men had a higher case fatality rate than women.

Its helpful to study sexdifferences in mice because it takes behavioral influences out of the equation,says Stanley Perlman, a virologist at the University of Iowa in Iowa City. Forexample, as reports from China indicated that more men than women were havingsevere cases of COVID-19, some also noted this could be due to the fact thatmore Chinese men than women smoke. China was also among the five countries thatSARS cases were concentrated in.

Perlmans team compared how male and female mice did when infected with a mouse-adapted version of SARS-CoV,the virus that causes SARS, and reported the results in the Journal of Immunology in 2017. Among middle-agedmice, those 8 to 9 months old, all of the males died within eight days of beinginfected, but only 10 percent of the females did by day 12. Males had higheramounts of the virus in their lungs than females did, suggesting the maleswerent clearing the virus effectively. The males also had a prolonged,unhelpful inflammatory response.

Headlines and summaries of the latest Science News articles, delivered to your inbox

When the research teamremoved the ovaries from 12 female mice to prevent estrogen from being made, about85 percent of the mice died after infection, compared with close to 20 percentof 12 females with their ovaries. Without estrogen, the female mice were nowas sensitive to the infection as male mice, Perlman says. While I wouldntclaim its the whole story, estrogen is a big part of the story.

Klein and Perlman both haveplans to study differences in the male and female response to COVID-19. In caseswhen the bodys own immune response contributes to a viral disease, it might beexpected women would fare worse, Klein says, because a strong immune responsecan lead to too much damaging inflammation. And with COVID-19, theres a lot ofconcern about the detrimental effect of increased inflammation in the lungs.

But what happens during COVID-19might be different. This aberrant inflammation might be higher in males thanfemales, Klein says.

See the original post here:
COVID-19 kills more men than women. The immune system may be why - Science News

Read More...

Covid-19 immunity and testing, explained – Vox.com

Friday, April 24th, 2020

The Covid-19 coronavirus meets its most formidable foe the moment it enters the human body.

The immune system is waiting, ready for action, and it determines who dies and who survives. It is why the vast majority of the infected have recovered from the disease.

Yet one of the most important unknowns is why some peoples immune systems are up to the task of clearing out the virus while others are sluggish or overreact, leading to death. Just as vexing:

Its helpful in thinking through these unanswered questions to understand how the immune system works (collectively and in individuals), how immunity testing works, and how immunity to similar viruses changes over time. Its also comforting to know that if you get Covid-19, your body will try very, very hard to save you. And if it doesnt, it could be because it tried too hard.

So here is a guide to the immune system: antibodies, serological tests, reinfection, and immunological memory, explained.

The first thing to know about the immune system is that it is not simple. At all.

A huge array of cells and chemicals your body produces work in concert to clear a foreign invader from your body. Theres a lot of elegance to this whole system, Akiko Iwasaki, an immunologist at the Yale School of Medicine, says. Its like an orchestra. All these cells and chemicals have to work in concert each with a different part to play to defeat the virus.

A viral infection begins when a virus enters a cell of your body. In the case of Covid-19, which is transmitted mostly by respiratory droplets, maybe that takes place somewhere in the lining of your nose or in the area of your lungs directly in contact with the air you inhale.

The virus then attaches to a cell via a protein on the cells surface called ACE-2 and lets itself in.

There, it begins to wreak havoc. The virus hijacks the cells machinery to make copies of itself. Those copies break out of the cell and then spread around your body. The copies enter more of your cells, make more copies, and so on. This is going viral, in the literal sense, and its a process your body works furiously to stop.

If the immune system is an orchestra in concert, its music can be broken down into two movements.

First, the opening: the innate immune response. This is the base-level protection you have to defend against infections even those your body has never seen before.

Iwasaki explains that every cell of your body has something of its own immune system in miniature. Your cells have a mechanism to detect virus infection, she says. Every cell is looking out for telltale genetic signs of viral replication. Once thats found, your cells start secreting these cytokines [signaling molecules] to tell the neighboring cells that theres a viral infection, she says. It will signal that cell to make a lot of antiviral proteins. Every part of the viral life cycle is targeted by hundreds of genes that are induced by this.

The innate immune response will then try to stop the virus in its tracks there, but it can fail, as we know. Viruses those sneaky bastards have evolved ways to counter this initial response. The viruses might encode proteins that degrade some of these signaling molecules, Iwasaki says. Even though we have this amazing system, viruses try to circumvent it.

If the innate immune system cant get rid of the infection, the second movement in this orchestration begins: the adaptive immune system. It has a vast array of instruments, each tuned to a specific task.

There are dendritic cells, which act as messengers from the innate immune system and tell the adaptive immune system which viral proteins it should seek out and destroy. There are killer T-cells, which hunt down and kill cells that have been infected. There are helper T-cells, which stimulate killer T-cells and recruit yet another class of cells called macrophages to gobble up infected cells, and they also stimulate B-cells, which bring this whole concert to a crescendo.

B-cells are critically important because they produce antibodies. These are little proteins that bind, specifically, to a single distinct part of a virus or pathogen and make it unable to hijack your cells. Antibodies can also identify invaders for other immune cells to destroy, and they can mark infected cells for destruction before a virus can burst out. And after an infection fades, the antibodies that linger can prevent the same virus from rising again.

But this process takes time.

When you first get infected with SARS-Cov-2, it usually takes anywhere from 10 to 14 days to make antibodies that are effective, says Vineet Menachery, an immunologist who studies coronaviruses at the University of Texas Medical Branch. That immunity actually peaks between four and eight weeks after youve been infected. The antibodies are really powerful at that point.

It takes a long time because an antibody has to be unique for the virus its trying to protect against. It takes a while and some trial and error to both build an antibody that can perfectly bind to the contours of the virus and to produce millions of copies of that antibody. The magnitude of potential antibodies is somewhere in the neighborhood of quadrillions or quintillions, Angela Rasmussen, a Columbia University virologist, says. But your immune system can narrow the choices down to the right formulation to clear the virus from your body.

The process isnt simple, but you can be in awe of it, like you can be in awe of a timepiece constructed from hundreds of delicately selected parts. I teach an entire semester course on this, Iwasaki says. This is the delicate process that a vaccine is trying to replicate artificially.

This antibody construction process can backfire, however. In some cases, antibodies bind to the virus, Iwasaki explains, and instead of blocking the virus, theyre taken up by white blood cells. Those white blood cells then go haywire, producing molecules called cytokines. Ordinarily, these chemicals promote inflammation throughout the body.

Inflammation is something that makes us feel sick, but it also helps us survive. People often think of swelling when they think of inflammation, Rasmussen says. Swelling occurs because cells from your immune system are rushing into the site of the infection. These immune cells have to get out of your blood vessels, she says, in order to corral the infection. Its a lovely process called rolling extravasation, she says. Your tissue gets inflamed because the balance of fluid is being changed.

But sometimes, so many cytokines are released that they trigger white blood cells to turn against healthy cells. That can then lead to organ failure and death. And that ultimately makes the disease as bad as it is, Iwasaki says.

Its unclear why a cytokine storm, as this reaction is called, might impact some people severely and not others, though there are indications that aging is a factor, as are underlying conditions like high blood pressure and diabetes. Researchers are also now looking for genetic clues to see who is most at risk. Thankfully, though, doctors do have some insights into how to treat this overreaction.

This whole orchestra ends when the immune system neutralizes all the virus in the body. That doesnt always mean the virus is purged; many viruses can linger in a latent state in the body without reproducing or causing symptoms. These latent viruses can flare up when the immune system is weakened, causing opportunistic infections. At the same time, youll be left with antibodies circulating in your blood.

But for reasons scientists dont quite understand, for some infections and notably, in other types of coronavirus infections antibody levels can wane over a period of years.

So how do doctors and scientists know if this process has been successful? How can they know if someone is now immune to the virus that causes Covid-19?

They test for it.

In particular, blood tests, also known as immunity tests or serological tests, can reveal who possesses antibodies to the virus. Deploying these tests will help answer a lot of questions. Most basically, it can help a person know if they have had Covid-19.

On a larger scale if deployed in well-designed studies serological tests could reveal the complete picture of the pandemic. They can also help scientists answer basic questions like:

Serological tests could also potentially allow people who have immunity to return to work. That could be a huge boost to front-line health workers who may have been exposed to the virus but are desperately needed back in action.

Just finding the antibodies isnt always enough, though. Scientists also need to do additional tests to make sure those antibodies are potent.

There are two main types of antibody tests, Menachery explains. The first just looks for antibodies and can be completed in a few hours. This is called an ELISA test (short for Enzyme Linked Immunosorbent Assay). And it doesnt provide the most complete picture of immunity.

The second test is more involved, and rarer. Its called a serum neutralization test, and it takes a few days to process. It not only looks for antibodies, it then exposes those antibodies to a virus in a cell culture to see how effective the antibodies are in stopping the virus.

Ideally, scientists will correlate the two tests and figure out which concentrations of antibodies confer the highest level of immunity. This work is ongoing, Menachery says. Its still not known what levels of antibodies are needed to have lasting, protective immunity. (What also remains to be shown: that the presence of antibodies also means you cant give the virus to someone else.)

These tests are useful, but they dont answer everything. As noted earlier, it takes days, if not weeks, for the body to produce antibodies. So a negative antibody test doesnt mean the virus isnt present. And since antibodies are produced during an infection and linger after its cleared, a positive antibody test doesnt mean that the virus is no longer active.

Confirming whether someone can still spread Covid-19 requires a separate genetic test like an RT-PCR test that detects the active virus.

Even if people do become immune, one thing we dont know about still is how long that immunity would last, Rasmussen says. And thats unfortunately not something we can determine until we wait months or years in the future, and test again and see if those antibodies are still there.

For reasons scientists dont quite understand, for some infections, your immunity never wanes. People who are immune to smallpox, for example, are immune for life: Antibodies that protect against smallpox have been found as long as 88 years after a vaccination.

Less reassuring here is that scientists have observed antibody levels to other coronaviruses (there are four coronavirus strains that infect people as the common cold) can wane over a period of years. A few weeks after an infection, antibody levels will be at their highest. But a year from now, that number is likely going to be a little bit lower, and five years from now its likely to be potentially a lot lower or a little bit lower, and we dont know the factors that change that, Menachery says.

However, even if you lose the antibodies, it doesnt mean you are again completely susceptible to the virus. Yes, none of this is simple.

There have been a few experiments where volunteers were willingly exposed to a coronavirus strain that produces a common cold. These studies show its common for the antibodies to these other coronavirus strains to decline after a year or so.

The majority of people that dont have serum neutralizing antibodies [i.e., antibodies that take out the virus], they get infected again, but they didnt get that sick, Menachery says. You couldnt do this type of test for Covid-19, he adds; its too dangerous.

There have been reports of a few patients out of China who had mild symptoms of Covid-19 who did not have detectable neutralizing antibodies after recovery, though they did have another form of antibody that binds to the virus. Its unclear whether they have protective immunity, Nature reports. Yes, there is more than one type of antibody, and they do different things, because none of this is simple.

Luckily, even if your antibodies against a coronavirus decline, your body has a backup plan.

Certain types of B-cells recall, these are the ones that make antibodies become memory B-cells. These save the instructions for producing a particular antibody, but they arent active. Instead, they hide out in your spleen, in your lymph nodes, perhaps at the original site of your infection waiting for a signal to start producing antibodies again.

With the memory B-cells in reserve, instead of waiting two weeks or more to get antibody production going, youll only have to wait maybe two or three days, Menachery says. So that means, yes, you can get infected again, but you may not even know youre sick. If you do get sick, maybe its a very minor infection.

Generally, he says, the more severe your infection, the more antibodies your immune system will produce, and the longer theyll stay in your bloodstream post-infection. So, he says, there is some concern that if you had a mild infection that your level of protection may not last long.

You may have seen some reports of people testing positive a second time for Covid-19 after recovering. The experts we spoke to say these reports are likely due to flaws in testing. I think the risk of being infected more than once from SARS-CoV-2 is nil, says Gregory Gray, an infectious disease epidemiologist at Duke University, in an email.

That may be because as you progress in the illness, the testing for Covid-19 becomes more inconsistent.

Often at the time that virus diseases present themselves, its fairly far into the replication of that virus in that person, says Diane Griffin, a professor of microbiology and immunology at the Bloomberg School of Public Health at Johns Hopkins University. Many symptoms of virus disease are actually manifestations of the immune response to the disease. Often things are starting to get better at the time youre starting to figure out someone even has a virus infection.

At least in the short term, its probably more the case that the people who have tested positive after recovering havent completely cleared the virus from their system or that a prior negative test was inaccurate.

Over the long term, the immune system itself becomes less effective with advancing age. And as people get older, they can acquire more chronic illnesses that can hamper the response to a virus, even if its one the immune system recognizes. It will be years, though, before scientists can understand what aging means for immunity to Covid-19.

The Centers for Disease Control and Prevention is now conducting serological surveys for Covid-19 antibodies in several places across the US.

Its an attempt to figure out who was previously infected with the virus, particularly if they never exhibited symptoms. A survey like this can show the actual background rate of infection and answer critical questions like what proportion of people have been infected without showing symptoms and where the virus has spread in a population, and quantify the overall rates of severe complications. Knowing these variables can help health officials better target interventions.

Many people who may have been infected also want to know if they are immune so they can safely leave lockdowns. Countries like Germany are even considering granting immunity passports so individuals can return to work.

Such testing could make a difference in a handful of cases, like for doctors and nurses who were infected or may have been exposed but are desperately needed back in action. But serological testing is unlikely to be a wholesale solution to reopening the economy.

Again, scientists are still uncertain about the robustness and duration of immunity that a Covid-19 infection confers, so a positive antibody test at this point doesnt guarantee that one can safely end social distancing measures. If immunity does fade after a year or two, the same person could be vulnerable to reinfection.

Meanwhile, to reopen schools, shops, and offices across the board, large numbers of people would have to have immunity. Without a vaccine, that would mean that the virus would have to infect vast swaths of the population, in the process sending thousands to the hospital and to their graves. That is exactly what measures like lockdowns and social distancing are trying to avoid.

While this outbreak has been ghastly, it has not been so bad as to bring about herd immunity in any quick time frame. There have been some imperfect serological studies that suggest the virus has infected more people than previously estimated. But even if true, the studies dont mean were anywhere close to achieving herd immunity.

So its unlikely that immunity can be a benchmark for when its okay to go back to normal across the population, and even in individual cases, it requires careful consideration of risks and benefits.

For those who have not yet contracted the virus, the main form of protection from Covid-19 right now is prevention. But there are several options scientists are studying that could help those who were never infected fend off the illness.

Chief among them is a vaccine. A vaccine can take various forms, including a weakened version of the virus itself, a small piece of the virus, or genetic material that prompts the immune system to manufacture antibodies to the virus.

Developing a vaccine for SARS-CoV-2 would be the ideal solution to the Covid-19 pandemic since its a form of prevention that would also hasten the end of costly measures like lockdowns, quarantines, and social distancing.

But its a time-consuming approach. Many experts estimate that it will take at least a year to develop a vaccine for the new coronavirus.

Vaccines can also pose risks. A small number of people can have dangerous adverse reactions to a vaccine, like severe allergies. In rare cases, vaccines can cause a phenomenon called immune enhancement, where the vaccine makes the recipients immune system overreact to the virus target, leading to a more severe disease than in those who were unvaccinated.

Though these risks are small, vaccines have to be delivered to millions of people. Thats why vaccine development focuses so much on safety and reducing the risks of complications as much as possible. Researchers are looking into various ways to speed up development, including human challenge trials where volunteers are deliberately exposed to the virus to test their immunity with and without a vaccine.

Another tactic under investigation is using convalescent plasma. The idea is to harvest the liquid part of blood, including proteins used for clotting, from people who have survived Covid-19. This plasma contains antibodies to the virus, so scientists are seeing whether it can help people with active infections get better. Researchers are also studying whether convalescent plasma can be used as a prophylactic to prevent Covid-19 in the first place.

Companies are also developing antibodies to SARS-CoV-2 using mice genetically engineered to have human immune systems. These antibodies can also be used to treat or prevent the disease.

But antibody transfusions, whether they come from Covid-19 survivors or were created in a lab, only confer protection against the virus for a few months.

The long-term strategy is to get enough people in a population immune to the virus so that it no longer spreads easily. This is known as herd immunity. It usually requires between 70 and 90 percent of a group of people to be immune in order to be effective, depending on the contagiousness of the virus.

With a large enough share of immunity in the population, even the remaining people who are not immune face a much lower likelihood of being infected. With few susceptible hosts in close proximity, pockets of infection quickly fade out. The question is whether this herd immunity is attained through vaccination or through infection.

The latter would not be ideal since it would involve millions getting sick from Covid-19. The United Kingdom was pursuing this approach back in early March but backed off its herd immunity strategy of limiting restrictions on movement and allowing people to be exposed. The country changed course when forecasters revealed that millions would likely contract the virus, overwhelming the UKs health system. Sweden has adopted a similar approach and is now facing vastly more Covid-19 cases than its neighbors.

Its also hard to gauge how close any country is to herd immunity since many people have likely been infected with the virus without knowing it. Figuring this out would require extensive testing for antibodies. And not everyone develops the same level of immunity from an infection. So vaccinating people against Covid-19 is the safer strategy.

Until then, widespread testing to identify the infected, isolating them, and tracing their contacts could help ease some of the pandemic control measures in place now.

How about what we can do as individuals?

Short of drugs like interferons, there isnt much a person can do to boost their immune system or their response to Covid-19, despite what various supplements promise.

The best Covid-19 approach for individuals is healthy habits maintain good hygiene, exercise, eat a balanced diet, get plenty of sleep, stay hydrated, manage any chronic health conditions like diabetes, and limit exposure to pollution.

Though the Covid-19 pandemic has been raging for several months, a lack of key information from how many people were infected to the origins of the disease continues to hamper the response.

More science on almost every aspect of this new virus is needed, but in this pandemic, as with previous ones, decisions with great consequences must be made before definitive data are in, wrote Harvard epidemiologist Marc Lipsitch in a column in the New York Times.

But the unknowns around immunity to the disease may be the most critical because they stand between the untenable present and a return to normal. Meanwhile, pressure is mounting to relax restrictions on movement to allow life to continue. With incomplete information, policymakers still have to make decisions that depend on immunity, but this can be done in ways that reduce risk.

The best approach is to construct a conceptual model a set of assumptions about how immunity might work based on current knowledge of the immune system and information about related viruses, and then identify how each aspect of that model might be wrong, how one would know and what the implications would be, Lipsitch wrote.

This is no easy task. It still might be the case that what we learn about immunity may not be enough for everything to go back to normal. We may need to wait, patiently, for a vaccine.

One advantage scientists have in the Covid-19 pandemic that they didnt have in prior outbreaks is an unparalleled level of information-sharing among researchers around the world. Researchers are posting their preliminary findings online for the world to scrutinize and working across borders, collaborating on an unprecedented scale.

That has led to unknowns becoming known faster than ever. But the disease is continuing to spread, and the drastic pandemic response measures cant continue forever, so some difficult choices lie ahead.

Support Voxs explanatory journalism

Every day at Vox, we aim to answer your most important questions and provide you, and our audience around the world, with information that has the power to save lives. Our mission has never been more vital than it is in this moment: to empower you through understanding. Voxs work is reaching more people than ever, but our distinctive brand of explanatory journalism takes resources particularly during a pandemic and an economic downturn. Your financial contribution will not constitute a donation, but it will enable our staff to continue to offer free articles, videos, and podcasts at the quality and volume that this moment requires. Please consider making a contribution to Vox today.

Read more from the original source:
Covid-19 immunity and testing, explained - Vox.com

Read More...

Page 9«..891011..2030..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick